Table 1.
Clinical data for West Nile virus-infected subjects.
| ID | Age at onset/blood draw* | Disease status | Diagnosis | WNV E IgG immunoblot | PRNT serum titer |
|---|---|---|---|---|---|
| PC1 | 48* | post-conv. | WNM | +++++ | 1:80 |
| PC2 | 44* | post-conv. | Asymp | ++++ | 1:640 |
| PC3 | 26* | post-conv. | WNF | +++ | 1:80 |
| PC4 | 21* | post-conv. | WNF | +++++ | 1:80 |
| RI1 | 67 | recent | WNE | ++ | 1:80 |
| RI2 | 30 | recent | Asymp | +++++ | 1:40 |
| RI3 | 64 | recent | WNE | +++++ | 1:40 |
| RI4 | 65 | recent | Asymp | +++ | 1:40 |
| RI5 | 37 | recent | WNE | +++++ | 1:40 |
| RI6 | 31 | recent | WNF | +++++ | 1:80 |
| RI7 | 59 | recent | Asymp | +++++ | 1:40 |
*
Age of the donor at the time of blood draw.
WNE, encephalitis;WNF, febrile illness; WNM, meningitis; Asymp, asymptomatic infection. PRNT indicates the dilution of serum needed to achieve 90% reduction of WNV growth in Vero cells. Immunoblot scale maximum is five +++++, corresponding to the reactivity with a known positive WNV patient serum.